Human leukocyte antigen polymorphisms: Variable humoral immune responses to viral vaccines

Expert Review of Vaccines

Volumn 5, Issue 1, 2006, Pages 33-43

  Ovsyannikova, Inna G ^a   Dhiman, Neelam ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody formation; Antigen processing; Antigens; Cytokines; Human leukocyte antigens; Humoral immunity; Measles; T cells; Viral vaccines

Indexed keywords

HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; RUBELLA VACCINE; VIRUS VACCINE;

GENETIC VARIABILITY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; MUMPS; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; HLA ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; VIRAL VACCINES;

EID: 33646490633     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.1.33     Document Type: Review

References (123)

1. Centers for Disease Control. Ten great public health achievements - United States, 1900-1999. MMWR (1999).
2. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63-75 (2001). Provides a good review of issues relating to the measurement of vaccine immune response.
3. Ball TM, Serwint JR. Missed opportunities for vaccination and the delivery of preventive care. Arch. Pediatr. Adolesc. Med. 150, 858-861 (1996).
4. Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5, 417-427 (2004).
5. Dhiman N, Bonilla R, O'Kane D, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20, 22-30 (2002).
6. De Groot AS, Sbai H, Aubin CS, McMurry J, Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80, 255-269 (2002).
7. Dhiman N, Bonilla RG, Jacobson RM, O'Kane D, Poland GA. Differential HLA gene expression in measles vaccine seropositive and seronegative subjects: a pilot study. Scand. J. Infect. Dis. 35, 332-336 (2003).
8. Hayney MS, Poland GA, Jacobson RM et al. Relationship of HLA-DQA1 alleles and humoral antibody following measles vaccination. Int. J. Infect. Dis. 2, 143-146 (1998).
9. Hayney MS, Poland GA, Jacobson RM, Schaid DJ, Lipsky JJ. The influence of the HLA-DRB1*13 allele on measles vaccine response. J. Invest. Med. 44, 261-263 (1996).
10. Jacobson RM, Poland GA. The genetic basis for measles vaccine failure. Acta Paediatr. 445(Suppl.), 43-47 (2004).
11. Jacobson RM, Poland GA, Vierkant RA et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum. Immunol. 64, 103-109 (2003). Demonstrates a basis for the genetic contribution to measles vaccine response.
12. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol. 65, 1506-1515 (2004).
13. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J. Infect. Dis. 191, 515-519 (2005). Demonstrates a basis for the genetic contribution to rubella vaccine response.
14. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22, 1914-1920 (2004).
15. Poland GA, Jacobson RM. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10, 208-215 (1998).
16. Poland GA, Jacobson RM, Schaid DJ, Moore SB, Jacobsen SJ. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 16, 1869-1871 (1998).
17. Poland GA, Ovsyannikova IG, Jacobson RM et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20, 430-438 (2001). Demonstrates a basis for the genetic contribution to measles vaccine response.
18. St Sauver JL, Ovsyannikova IG, Jacobson RM et al. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185, 1545-1549 (2002).
19. St Sauver JL, Schaid DJ, Vierkant RA et al. Associations between measles antibody levels and the protein structure of class II human leukocyte antigens. Hum. Immunol. 64, 696-707 (2003).
20. Poland GA. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am. J. Hum. Genet. 62, 215-220 (1998).
21. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506-512 (1987).
22. Huston DP. The biology of the immune system. JAMA 278, 1804-1814 (1997).
23. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228 (1995).
24. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719 (1994).
25. Khalil-Daher I, Boisgérault F, Feugeas JP, Tieng V, Toubert A, Charron D. Naturally processed peptides from HLA-DQ7(a1*0501- b1*0301): influence of both α and β chain polymorphism in the HLA-DQ peptide binding specificity. Eur. J. Immunol. 28, 3840-3849 (1998).
26. Klein J, Sato A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702-709 (2000).
27. Klein J, Sato A. The HLA system. Second of two parts. N. Engl. J. Med. 343, 782-786 (2000).
28. Trowsdale J, Ragoussis J, Campbell RD. Map of the human MHC. Immunol. Today 12, 443-446 (1991).
29. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol. Cell Biol. 77, 304-311 (1999).
30. Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis. 5, 285-294 (1999).
31. Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin. Immunol. Immunopathol. 67, 171-177 (1993).
32. Chesler DA, Reiss CS. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13, 441-454 (2002).
33. Gans HA, Maldonado Y, Yasukawa LL et al. IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J. Immunol. 162, 5569-5575 (1999). Provides important evidence that cellular immunity to measles may be limited in infants compared with adults.
34. Paludan SR. Interleukin-4 and interferon-g: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48, 459-468 (1998).
35. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann. Rev. Immunol. 16, 111-135 (1998).
36. Neuberger MS, Ehrenstein MR, Rada C et al. Memory in the B-cell compartment: antibody affinity maturation. Philosoph. Trans. Royal Soc. B: Biological Sci. 355, 357-360 (2000).
37. Welsh RM, Selin LK, Szomolanyi-Tsuda E. Immunological memory to viral infections. Ann. Rev. Immunol. 22, 711-743 (2004).
38. Fehr T, Naim HY, Bachmann MF et al. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nature Med. 4, 945-948 (1998).
39. Milich DR. Synthetic T and B cell recognition sites: implications for vaccine development. Adv. Immunol. 45, 195-282 (1989).
40. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol. Rev. 18, 99-117 (1996).
41. Burton DR. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 706-713 (2002).
42. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103, 133-138 (2004).
43. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J. Clin. Microbiol. 24, 157-160 (1986).
44. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181, 1133-1137 (2000).
45. Palache AM. Antibody response after influenza immunization with various vaccine doses: A double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11, 3-9 (1993).
46. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70, 767-777 (1972).
47. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270, 1956-1961 (1994).
48. Foster DA, Talsma A, Furumoto-Dawson A et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am. J. Epidemiol. 136, 296-307 (1992).
49. Mullooly J, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann. Intern. Med. 121, 947-952 (1994).
50. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 18, 957-1030 (2000).
51. Beyer WEP, de Bruijn IA, Palache AM, Westendorp RGJ, Osterhaus ADME. Protection against influenza after annually repeated vaccination. A meta-analysis of serologic and field studies. Arch. Intern. Med. 159, 182-188 (1999).
52. Plotkin SA. Rubella Vaccine. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders, PA, USA, 409-440 (1999).
53. O'hea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J. Infect. Dis. 148, 639-647 (1983).
54. Schwarzer S, Reibel S, Lang AB et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 16, 298-304 (1998).
55. Fedson DS, Shapiro ED, LaForce FM et al. Pneumococcal vaccine after 15 years of use. Another view. Arch. Intern. Med. 154, 2531-2535 (1994).
56. Orenstein WA, Albrecht P, Herrmann KL, Bernier R, Bart KJ, Rovira EZ. The plaque-neutralization test as a measure of prior exposure to measles virus. J. Infect. Dis. 155, 146-149 (1987).
57. Chen RT, Markowitz LE, Albrecht P et al. Measles antibody: Reevaluation of protective titers. J. Infect. Dis. 162, 1036-1042 (1990). Provides empiric evidence of disease occurrence despite measurable humoral vaccine response.
58. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - seven-year results. Arch. Intern. Med. 151, 1634-1636 (1991).
59. West DJ, Calandra GR. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14, 1019-1027 (1996).
60. Vandepapeliere P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23, 2591-2601 (2005).
61. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735-746 (1996).
62. O'Ryan ML, Matson DO, Estes MK, Pickering LK. Antirotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J. Infect. Dis. 169, 504-511 (1994).
63. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J. Infect. Dis. 170, S24-S31 (1994).
64. Poland GA, Jacobson RM. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch. Intern. Med. 154, 1815-1820 (1994).
65. Poland GA. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine 17, 1719-1725 (1999).
66. Pabst HF, Spady DW, Carson MM, Krezolek MP, Barreto L, Wittes RC. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 17, 1910-1918 (1999).
67. Pabst HF, Spady DW, Carson MM, Stelfox HT, Beeler JA, Krezolek MP. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15, 10-14 (1997).
68. Ward BJ, Boulianne N, Ratnam S, Guiot M-C, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172, 1591-1595 (1995).
69. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: Implications for vaccine strategies against intracellular pathogens. Exp. Rev. Vaccines 3, 23-34 (2003).
70. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J. Infect. Dis. 168, 275-281 (1993).
71. Ovsyannikova IG, Reid KC, Jacobson RM, Oberg AL, Klee GG, Poland GA. Cytokine production patterns and antibody response to measles vaccine. Vaccine 21, 3946-3953 (2003).
72. Howe RC, Dhiman N, Ovsyannikova IG, Poland GA. Induction of CD4 T cell proliferation and Th1-like cytokine responses in vitro to measles virus. Clin. Exp. Immunol. 140, 333-342 (2005).
73. Ovsyannikova IG, Jacobson RM, Ryan JE et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56, 798-807 (2005). Demonstrates that cytokine responses to measles are genetically restricted in part by human leukocyte antigen (HLA) genes.
74. Schnorr J-J, Cutts FT, Wheeler JG et al. Immune modulation after measles vaccination of 6-9 months old Bangladeshi infants. Vaccine 19, 1503-1510 (2001).
75. World Health Organization. Global measles mortality reduction and regional elimination strategic plan 2001-2005. (2001).
76. World Health Organization. Proceedings of the Conference on Global Disease Elimination and Eradication as Public Health Strategies. Atlanta, GA, USA, 23-25 February (2000).
77. Tan P-L, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 19, 2434-2439 (2001). Demonstrates the relative importance of the genetic contribution to the variation in quantitative humoral response when environmental influences are held constant.
78. Hohler T, Reuss E, Evers N et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360, 991-995 (2002).
79. Newport MJ, Goetghebuer T, Weiss HA et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122-129 (2004). Demonstrates that genetic factors, including non-HLA genes, modulate immune responses to infant vaccination.
80. Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun. Dis. Public Health 6, 106-112 (2003).
81. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175, 495-502 (1992). Demonstrates a basis for the genetic contribution to nonresponsiveness to hepatitis B vaccine.
82. Mineta M, Tanimura M, Tana T, Yssel H, Kashiwagi S, Sasazuki T. Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int. Immunol. 8, 525-531 (1996).
83. Langö-Warensjö A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 52, 374-380 (1998).
84. Hsu H-Y, Chang M-H, Ho H-N et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 11, 1437-1440 (1993).
85. Walker M, Szmuness W, Stevens C, Rubinstein P. Genetics of antiHBs responsiveness. 1. HLA-DR7 and non-responsiveness to hepatitis vaccination. Transfusion 21, 601 (1981).
86. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 51, 593-604 (1998).
87. Caillat-Zucman S, Gimenez J-J, Wambergue F et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int. 53, 1626-1630 (1998).
88. Martinetti M, De Silvestri A, Belloni C et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin. Immunol. 97, 234-240 (2000).
89. Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321, 708-712 (1989).
90. Caillat-Zucman S, Gimenez J-J, Albouze G et al. HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int. 43, S157-S160 (1993).
91. Alper CA. The human immune response to hepatitis B surface antigen. Exp. Clin. Immunogenet. 12, 171-181 (1995).
92. Hatae K, Kimura A, Okubo R et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur. J. Immunol. 22, 1899-1905 (1992).
93. McDermott AB, Cohen SBA, Zuckerman JN, Madrigal JA. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 17, 330-339 (1999).
94. McDermott AB, Zuckerman JN, Sabin CA, Marsh SGE, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50, 8-14 (1997).
95. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39, 978-988 (2004).
96. Lindemann M, Barsegian V, Siffert W, Ferencik S, Roggendorf M, Grosse-Wilde H. Role of G-protein p3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination. Virology 297, 245-252 (2002).
97. Hohler T, Stradmann-Bellinghausen B, Starke R et al. C4A deficiency and nonresponse to hepatitis B vaccination. J. Hepatol. 37, 387-392 (2002).
98. Schuenke KW, Cook RG, Rich RR. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum. Immunol. 59, 783-793 (1998).
99. Gelder CM, Lambkin R, Hart KW et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185, 114-117 (2002).
100. Lambkin R, Novelli P, Oxford J, Gelder C. Human genetics and responses to influenza vaccination: clinical implications. Am. J. Pharmacogenomics 4, 293-298 (2004).
101. + T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J. Virol. 70, 4787-4790 (1996).
102. Saririan K, Wali A, Almeida RP, Russo C. Increased serum HLA class I molecule levels in elderly human responders to influenza vaccination. Tissue Antigens 42, 9-13 (1993).
103. Saririan KK, Contini P, Indiveri F, Gross PA, Russo C. Serum HLA class I levels in elderly humans. Utilization in following the response to influenza vaccine. Hum. Immunol. 40, 202-209 (1994).
104. Brunell PA, Weigle K, Murphy D, Shehab Z, Cobb E. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 250, 1409-1412 (1983).
105. Poland GA, Jacobson RM, Colbourne SA et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 17, 1525-1531 (1999).
106. Ovsyannikova IG, Johnson KL, Muddiman DC, Vierkant RA, Poland GA. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J. Virol. 78, 42-51 (2004).
107. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 47, 1-57 (1998).
108. Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 38, 1-18 (1989).
109. Centers for Disease Control and Prevention. Measles eradication: Recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 46, 1-20 (1997).
110. St. Sauver JL, Dhiman N, Ovsyannikova IG et al. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. Hum. Immunol. 66, 788-798 (2005).
111. Mitchell LA, Zhang T, Tingle AJ. Differential antibody responses to rubella virus infection in males and females. J. Infect. Dis. 166, 1258-1265 (1992).
112. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. Br. Med. J. 304, 1075-1078 (1992).
113. Mitchell LA. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. J. Med. Microbiol. 48, 1075-1080 (1999).
114. Hsia S, Howell DN, Amos DB, Woodbury MA. Studies of viral antibody responses among Amish families. J. Immunol. 118, 1659-1664 (1977).
115. Hyoty H, Rasanen L, Lehto M et al. Cell-mediated and humoral immunity to mumps virus antigen. Acta. Pathol. Microbiol. Immunol. Scand. 94, 201-206 (1986).
116. Dawson DV, Ozgur M, Sari K, Ghanayem M, Kostyu DD. Ramifications of HLA class I polymorphism and population genetics for vaccine development. Genet. Epidemiol. 20, 87-106 (2001).
117. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405-411 (1996).
118. Mellins E, Woelfel M, Pious D. Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis. Hum. Immunol. 18, 211-223 (1987).
119. + T cell responses directed against influenza viral antigens postinfluenza vaccination. J. Immunol. 171, 3163-3169 (2003).
120. Ou D, Mitchell LA, Décarie D, Tingle AJ, Nepom GT. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Hum. Immunol. 59, 149-157 (1998).
121. Haynes BF, Yasutomi Y, Torres JV et al. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: An HLA-based vaccine strategy. Trans. Assoc. Am. Physicians 106, 33-41 (1993).
122. Doolan DL, Southwood S, Chesnut R et al. HLA-DR promiscuous T cell epitopes from Plasmodium falciparum ore-erythrocytic-state antigens restricted by multiple HLA Class II alleles. J. Immunol. 165, 1123-1137 (2000).
123. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182, 1486-1496 (2000).